Is PMOS tied to dementia?

A study has explored the potential long-term adverse neurologic effects of polyendocrine metabolic ovarian syndrome.

In the study, published in the Journal of the Endocrine Society, investigators used the PubMed database to identify studies assessing the relationship between PMOS and cognitive impairment, brain structure and function, neurodegeneration, and Alzheimer’s disease and related dementias.

The investigators found that certain pathways — including insulin resistance, chronic inflammation, hormone dysregulation and cardiovascular dysfunction — could link PMOS with Alzheimer’s disease and related dementias. Patients may thereby present with biomarkers signaling neurodegeneration such as amyloid-beta plaque buildup, tau hyperphosphorylation, oxidative stress and cerebral metabolic deficiencies.

Despite the potential correlation identified in the study, the investigators stressed that co-existing metabolic dysfunction and comorbidities could also explain the neurologic findings. Therefore, they suggested that larger studies are needed to help elucidate the association between PMOS and cognitive decline.

Read more: Journal of the Endocrine Society

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.